-
Mashup Score: 0Predictive Factors Identified for Positive Response to Baricitinib in Alopecia Areata - 5 month(s) ago
In this study, several predictive factors for positive alopecia areata outcomes after baricitinib therapy were identified, including female sex and a lower SALT score before treatment.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Predictive Factors Identified for Positive Response to Baricitinib in Alopecia Areata - 5 month(s) ago
In this study, several predictive factors for positive alopecia areata outcomes after baricitinib therapy were identified, including female sex and a lower SALT score before treatment.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
A new study identified several predictors of positive outcomes with baricitinib treatment of #AlopeciaAreata. 📰 Some examples include lower pre-treatment SALT scores, shorter disease duration, and female sex. 👇To learn more, view our summary here👇 https://t.co/5T2K1bUKb2
-
-
Mashup Score: 0Clinical Quiz: ALLEGRO and Ritlecitinib for Alopecia Areata - 5 month(s) ago
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
In the latest HCPLive Clinical Quiz, you can test your awareness of the June 2023 approval of ritlecitinib, the 1st treatment specifically for adolescents/young adults with severe #AlopeciaAreata. The quiz focuses on the landmark phase 2b/3 ALLEGRO trial: https://t.co/YpSjTVL5vt
-
-
Mashup Score: 1Study Suggests Ritlecitinib Effective Long-Term Among Patients with Alopecia Areata - 5 month(s) ago
These data highlight the effectiveness of long-term ritlecitinib treatment among those with alopecia areata and significant scalp hair loss.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
ICYMI: Ritlecitinib shows efficacy in #AlopeciaAreata patients with ≥25% scalp hair loss, achieving significant hair regrowth & patient-reported improvements. The ALLEGRO-LT study focused on those with alopecia totalis and universalis. View more here 👇 https://t.co/0dgGRNxXy2
-
-
Mashup Score: 0Alopecia Areata Risk in Patients With IBD Tied to Anti-TNF Use - 8 month(s) ago
Alopecia areata was more likely to develop in patients with inflammatory bowel disease (IBD) who were taking anti–tumor necrosis factor (TNF) therapy at the onset of the condition.
Source: www.ajmc.comCategories: General Medicine News, General Journals & SocietTweet-
#Alopeciaareata was more likely to develop in patients with inflammatory bowel disease (IBD) who were taking anti–tumor necrosis factor (TNF) therapy at the onset of the condition: https://t.co/Pk0pCyKpcS https://t.co/AWgiOohbLj
-
-
Mashup Score: 0Expert Insights on Deuruxolitinib for Alopecia Areata - 11 month(s) ago
Arash Mostaghimi, MD, MPA, MPH, assistant professor of dermatology, director of the inpatient dermatology consult service, and codirector of the Complex Medical Dermatology Fellowship at Brigham & Women’s Hospital, discusses the recent FDA approval of deuruxolitinib for the treatment of moderate to severe alopecia areata.
Source: www.ajmc.comCategories: General Medicine News, PayerTweet-
Tune in as Dr Arash Mostaghimi / @AMostaghimi of Brigham & Women's Hospital discusses the development and approval of deuruxolitinib for moderate to severe #alopeciaareata (AA). Learn more: https://t.co/TgUauTuwmn https://t.co/g8CKVnMTwJ
-
-
Mashup Score: 2
The phase 2 study achieved the primary end point of a >30% Severity of Alopecia Tool score improvement.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
âť—NEW: Soterios Pharma recently announced new positive topline results from its randomized, placebo-controlled, multi-dose, phase 2 clinical trial evaluating STS-01 for the treatment of mild to moderate #alopeciaareata. https://t.co/L9gcZs8rTT
-
-
Mashup Score: 2HRQoL of Patients with Alopecia Areata in Australia - 1 year(s) ago
The largest patient study across the continent found a direct link between the extent of hair loss and the negative impact on quality of life.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
To better understand the experiences of adults and adolescents with #alopeciaareata, researchers surveyed 337 patients on their health-related quality of life, with questions focusing on symptom severity, psychosocial wellbeing, and productivity. https://t.co/2TkIssxQS4
-
-
Mashup Score: 0
A systematic review presented at AAPA 2024 showed insignificant differences in treatment outcomes between oral JAK inhibitors and oral steroids based on alopecia outcomes like SALT.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
In a recent study, oral JAK inhibitors and corticosteroids were consistent with one another in treatment outcomes for #AlopeciaAreata. Want to learn more? View our summary here: https://t.co/zfXHd0kU5K
-
-
Mashup Score: 4Several Barriers Linked to Hindered Access of JAKi Therapy in Patients, Particularly Non-White, With Alopecia Areata - 1 year(s) ago
These challenges may exacerbate racial inequities in care access and quality, according to a new study.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
Patients with #alopeciaareata endure various challenges when attempting to obtain Janus kinase inhibitor therapy, and these challenges may exacerbate racial inequities in care access and quality, according to a new study. https://t.co/01Ie9lol2B
-
A new study identified several predictors of positive outcomes with baricitinib treatment of #AlopeciaAreata. 📰 Some examples include lower pre-treatment SALT scores, shorter disease duration, and female sex. 👇To learn more, view our summary here👇 https://t.co/5T2K1bUKb2